$VIR Income Statement | Understand Stock

$VIR

$11.57 +$0.53 (4.8%) Close

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Revenues:
Revenues not from contract
Collaboration revenue
Contract revenue
License revenue from a related party
License and collaboration revenue
Grant revenue
Other revenue
License
Total revenues

Operating expenses:
Cost of revenue
Research and development
Selling, general and administrative
Restructuring, long-lived assets impairment and related charges, net
Total operating expenses
Loss from operations
Other income:
Change in fair value of equity investments
Interest income
Other expense, net
Total other income
Loss before (provision for) benefit from income taxes
(Provision for) benefit from income taxes
Net loss
Net loss attributable to noncontrolling interest
Net loss attributable to Vir Bio
Net loss per share attributable to VirBio, basic (in USD per share)
Net loss per share attributable to VirBio, diluted (in USD per share)
Weighted-average shares outstanding, basic (in shares)
Weighted-average shares outstanding, diluted (in shares)

Comments